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a b s t r a c t
In this study, we demonstrated the potential of direct infusion mass spectrometry for the lipidomic
characterization of Alzheimer’s disease. Serum samples were extracted for lipids recovery, and directly
analyzed using an electrospray source. Metabolomic ﬁngerprints were subjected to multivariate analysis
in order to discriminate between groups of patients and healthy controls, and then some key-compounds
were identiﬁed as possible markers of Alzheimer’s disease. Major differences were found in lipids,
although some low molecular weight metabolites also showed signiﬁcant changes. Thus, important
metabolic pathways involved in neurodegeneration could be studied on the basis of these perturbations,
such as membrane breakdown (phospholipids and diacylglycerols), oxidative stress (prostaglandins,
imidazole and histidine), alterations in neurotransmission systems (oleamide and putrescine) and
hyperammonaemia (guanidine and arginine). Moreover, it is noteworthy that some of these potential
biomarkers have not been previously described for Alzheimer’s disease.
© 2014 Elsevier B.V. All rights reserved.
21
1. Introduction22
Multiple pathological disorders have been associated with23
Alzheimer’s disease (AD), involving abnormal protein aggregation24
in brain (amyloid  plaques and tangles of hyperphosphorylated25
 protein) [1] and other processes such as oxidative stress [2],26
mitochondrial dysfunction [3], neurotransmission changes [4], and27
others. In this context, the importance of metabolites for study-28
ing the pathogenesis of diseases has been demonstrated, since the29
metabolome is the biological level closer to phenotype [5]. Par-30
ticularly, lipids are very useful targets since play important roles31
in biological systems, so the global characterization of these com-32
pounds in a large-scale, or lipidomics, has a high potential in health33
survey [6]. In AD, lipids can be linked to several hallmarks of disease34
[7], principally dysregulation of membrane lipids, oxidative stress35
and vascular changes. Breakdown of cellular membranes is one of36
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the most characteristic features of neurodegeneration, associated 37
with abnormal metabolism of membrane lipids [8]. In this sense, 38
alterations in two families of compounds have been described; (i) 39
phospholipids, such as phosphocholines, phosphoethanolamines 40
and plasmalogens [9], and (ii) sphingolipids and related com- 41
pounds, such as sphingomyelins, ceramides or sulfatides [10]. On 42
the other hand, brain is particularly susceptible to oxidative dam- 43
age because of the high concentration of polyunsaturated fatty 44
acids (PUFAs) and high oxygen consumption rates. Thus, the con- 45
tribution of oxidative stress to AD also has consequences on the 46
lipidomic proﬁle, leading to the accumulation of typical markers of 47
lipid oxidation. An important group are the eicosanoids, oxidation 48
products of araquidonic acid through different enzymatic path- 49
ways [11]. Furthermore, the attack of reactive oxygen species (ROS) 50
causes lipidperoxidation, generating isoprostanes (free radical per- 51
oxidation of araquidonic acid) [12], neuroprostanes (from docosa- 52
hexaenoic acid) or aldehydes such as 4-hydroxynonenal and mal- 53
ondialdehyde [13]. Finally, ADhasbeenalso associatedwith several 54
vascular risk factors, such as the epsilon 4 allele of the apolipopro- 55
tein E (ApoE), elevated homocysteine levels, hyperlipidemia, 56
obesity or diabetes. These vascular defects could cause abnormal- 57
ities in the vascular system, speciﬁcally in cerebrovascular system 58
(atrophy, structural changes in the blood–brain barrier and inﬂam- 59
mation), which result in decreased cerebral blood ﬂow that ﬁnally 60
involves neuronal loss [14]. In this sense, the contribution of high 61
http://dx.doi.org/10.1016/j.jpba.2014.05.023
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levels of triglycerides, cholesterol, lipoproteins or fatty acids has62
been previously reported as one of the most important vascular63
factors in AD. For all these reasons, the characterization of global64
changes in lipids and theirmetabolites canbe interesting inorder to65
understand the role of these compounds in physiopathology of AD.66
The study and identiﬁcation of lipidomic biomarkers requires67
analytical techniqueswithhigh sensitivity and selectivity, andwide68
range of applicability to analyze the large number of molecules69
existing, with very different structures and functions. In this sense,70
mass spectrometry with soft ionization technologies as electro-71
spray (ESI) or atmospheric pressure chemical ionization (APCI)72
is emerging in this ﬁeld [15]. This platform offers capability for73
both quantitative and qualitative analyses and it may be coupled74
to separation techniques, principally chromatography and capil-75
lary electrophoresis. On the other hand, direct infusion of samples76
into the spectrometer is also possible, providing faster analy-77
sis and higher reproducibility, but it presents the disadvantage78
of isobaric interferences. For this, the analysis of complex sam-79
ples requires the use of high resolution and accuracy instruments80
such as time of ﬂight (TOF-MS), Fourier transform ion cyclotron81
resonance (FTICR-MS) or Orbitrap [16]. Moreover, the hybrid sys-82
tem Q-TOF-MS, which allows more accurate mass measurement83
than single TOF instrument and structural elucidation by MS/MS84
experiments [17], is gaining great importance in recent years in85
metabolomics [18,19], and particularly in lipidomics on the basis of86
multi-dimensional mass spectrometry-based shotgun lipidomics,87
or MDMS-SL [20–22].88
The present work represents a lipidomic approximation to89
Alzheimer’s disease based on direct infusion mass spectrometry90
analysis. Metabolic changes in blood serum samples of AD patients91
respect to healthy controls were evaluated by ESI-Q-TOFMS ﬁn-92
gerprinting, demonstrating the involvement of different classes of93
lipids and individualmolecular species of these compounds, aswell94
as low molecular mass metabolites.95
2. Material and methods96
2.1. Reagents and samples97
Methanol and chloroform (HPLC-grade) were purchased from98
Aldrich (Steinheim, Germany), and ammonium acetate was sup-99
plied by Merck (Darmstadt, Germany). Blood samples were100
obtained by venipuncture of the antecubital region after 8h101
of fasting, from 22 patients (10 male and 12 female, medium102
age 78.5±5y) newly diagnosed of sporadic Alzheimer’s disease103
(AD), according to the criteria of NINCDS-ADRDA [23], and 18104
matched healthy controls, HC (7 male and 11 female, medium age105
70.7±4.1 y). All samples were collected in BD Vacutainer SST II106
tubes with gel separator and Advance vacuum system, previously107
cooled in a refrigerator. The samples were immediately cooled and108
protected from light for 30min to allow clot retraction to obtain109
serum after centrifugation (3500 rpm for 10min). The serum was110
divided into aliquots in Eppendorf tubes and frozen at −80◦ C until111
analysis. The study was performed in accordance with the prin-112
ciples contained in the Declaration of Helsinki. All persons gave113
informed consent for the extraction of peripheral venous blood114
and controls subjects were studied by neurologists to conﬁrm the115
absence of neurological and cognitive disease.116
2.2. Sample treatment117
Extraction of serum samples was performed following a pro-118
cedure derived from the method proposed by Bligh and Dyer [24],119
employing a mixture of chloroform and methanol. In addition,120
since neutral lipids are not readily ionized by ESI, addition of121
ammonium ions was selected for analysis in positive ion mode. 122
In the case of negative ionization, any additive was employed. For 123
extraction, 50L of serum are mixed with 150L of methanol, 124
containing30mMammoniumacetate for ESI(+) andpuremethanol 125
for ESI(−) analysis. After stirring during 1min in vortex, which 126
causes the precipitation of proteins, the extract is combined with 127
200L of chloroform and again stirred for another minute. Finally, 128
sample is centrifuged at 10,000 rpm and 4 ◦C during 10min, and 129
organic phase is taken for analysis. 130
2.3. Instrumentation 131
The experiments were performed in a QSTAR XL Hybrid system 132
(Applied Biosystems, Foster City, CA, USA) using an electrospray 133
(ESI) source. The sampleswere introduced into themass spectrom- 134
eter using an integrated apparatus pump and a 1000L volume 135
Hamilton syringe at ﬂow rate 5Lmin−1. Data were obtained both 136
in positive and negative ion mode, acquiring full scan spectra for 137
0.2min in them/z range 50–1100with 1.005 s scan time. In positive 138
mode, the ion spray voltage (IS) was set at 3300V, the curtain gas 139
ﬂow at 1.13 Lmin−1 and the nebulizer gas ﬂow at 1.56 Lmin−1. The 140
source temperaturewasﬁxedat 60 ◦C,with adeclusteringpotential 141
(DP) of 60V and a focusing potential (FP) of 250V. In ESI(−), only 142
few parameters were modiﬁed respect ESI(+) method, with an ion 143
spray voltage at −4000V, a declustering potential (DP) of −100V 144
and a focusing potential (FP) of −250V. To acquire MS/MS spectra, 145
nitrogen was used as collision gas. 146
2.4. Data analysis 147
To carry out statistical analysis, spectra were submitted to peak 148
picking and matching of peaks across samples in order to reduce 149
the results into a two-dimensional data matrix of spectral peaks 150
and peak intensities, by using MarkerviewTM software (Applied 151
Biosystems). Then, SIMCA-PTM software (version 11.5, published 152
by UMetrics AB, Umeå, Sweden) was employed for statistical pro- 153
cessing. Partial least squares discriminant analysis (PLS-DA) was 154
performed to build predictive models in order to ﬁnd differences 155
between the groups of study (AD patients and healthy controls) 156
and further study of potential biomarkers. Quality of the model 157
was assessed by the R2 and Q2 values, provided by the software 158
(indicative of class separation and predictive power of the model, 159
respectively). 160
2.5. Compounds identiﬁcation 161
Identiﬁcation of signiﬁcant compounds was made matching the 162
experimental accurate mass and tandem mass spectra with those 163
available in metabolomic databases (HMDB, METLIN, KEGG and 164
LIPIDMAPS), using a mass accuracy of 50ppm. Moreover, different 165
classes of lipids were conﬁrmed based on characteristic fragmen- 166
tation patterns reported in literature. Phosphatidylcholines and 167
plasmenylethanolamines presented characteristic ions in negative 168
ionization mode at m/z 168.04 and 196.07, respectively [25]. In 169
addition, the fragmentation in the glycerol backbone and release 170
of the fatty acyl substituents enabled the identiﬁcation of individ- 171
ual species of phospholipids [26]. Finally, diacylglycerols [27], fatty 172
acid amides [28] and eicosanoids [29] were also conﬁrmed with 173
characteristic fragments described in the literature. 174
3. Results 175
3.1. Metabolomic proﬁles 176
Mass spectra of serum extracts provided abundant biochem- 177
ical information, considering the high number of signals that 178
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Fig. 1. ESI spectra of serum extracts in positive (A) and negative (B) modes.
could be detected. Furthermore, application of both positive and179
negative ionization modes allowed analyzing different subsets of180
metabolome according to the chemical nature of compounds, as181
reﬂected in the complementary proﬁles obtained (Fig. 1A and B).182
Therefore, a large number of metabolites can be studied combining183
the different spectral proﬁles, which provides a very characteristic184
metabolic ﬁngerprinting of serum samples.185
3.2. Multivariate analysis186
In order to discriminate between samples from Alzheimer’s dis-187
ease (AD) and healthy controls (HC), multivariate data analysis was188
employed. Partial least squares discriminant analysis (PLS-DA) was189
performed to carry out the classiﬁcation of the samples, building190
models that provide a clear separation between groups, visible in191
the scores plots both for positive and negative ionization modes192
(Fig. 2). Four components models clearly differentiate AD from HC193
samples, with high class separation predictive values (R2 =0.999 in194
both models). Moreover, cross-validation of these models was also195
successful, with Q2 values around 0.9.196
3.3. Selection of potential biomarkers197
The most discriminant signals were selected according to the198
Variable Importance in the Projection (VIP, predictive parameter199
provided by the software that indicates the importance of the200
variable in the model), for later study by MS/MS and identiﬁca-201
tion with metabolomic databases. Selecting only variables with VIP202
values greater than 2.0, numerous signals assigned to lipid com-203
pounds were identiﬁed as potential biomarkers in positive and204
negative ionization analyses (Tables 1 and 2). Furthermore, several205
low molecular weight metabolites also presented alterations in AD206
samples respect to healthy controls, both in positive and negative207
modes, listed in Table 3.208
4. Discussion209
Biomarkers identiﬁed could be associated with different210
pathologies of AD, as shown in this section. Thus, interpretation211
Fig. 2. Scores plots of the PLS-DA for ESI+ (a) and ESI− data (b). Black squares: AD Q5
patients; red circles: HC, healthy controls. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of the article.)
Table 1
Lipid biomarkers of AD in ESI+ analysis; (↑) increased in AD, (↓) decreased in AD.
m/z Compound Change
Diacylglycerols (DAGs)
591.49 C16:0/C18:3-DG (+H)
↑
614.55 C16:0/C18:0-DG (+NH4)
619.53 C18:3/C18:0-DG (+H)
634.52 C16:0/C20:4-DG (+NH4)
C18:2/C18:2-DG (+NH4)
C18:1/C18:0-DG (+NH4)
Eicosanoids
317.24 Prostaglandins, PGs (M+H+-H2O) ↑
Fatty acid amides (FAAs)
299.31 Oleamide (+NH4+) ↓
Table 2
Phospholipids as biomarkers of AD in ESI− analysis (decreased in AD).
m/z Compound
Phosphocholines (PtdCh)
802.55 C18:3/C20:4-PC (−H+)
806.55 C18:2/C20:3-PC (−H+)
C18:1/C20:4-PC (−H+)
814.51 C16:0/C20:5-PC (+Cl−)
840.52 C16:0/C22:6-PC (+Cl−)
C18:2/C20:4-PC (+Cl−)
C18:1/C20:5-PC (+Cl−)
842.53 C16:0/C22:5-PC (+Cl−)
C18:1/C20:4-PC (+Cl−)
C18:0/C20:5-PC (+Cl−)
868.55 C18:0/C22:6-PC (+Cl−)
870.55 C18:0/C22:5-PC (+Cl−)
Ethanolamine plasmalogens (PlsEt)
748.53 P18:1/C20:4-PlsEt (−H+)
774.55 P18:0/C22:6-PlsEt (−H+)
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Table 3
Other biomarkers of AD in ESI+ analysis; (↑) increased in AD, (↓) decreased in AD.
m/z Compound Change
ESI+
60.04 Guanidine (+H) ↓
89.06 Putrescine (+H) ↓
69.05 Imidazole (+H) ↓
209.11 Kynurenine (+H) ↑
126.02 Taurine (+H) ↓
ESI− 154.06 Histidine (−H) ↓173.10 Arginine (−H) ↓
of alterations can provide very valuable biochemical information212
about the disease.213
4.1. Membrane breakdown214
Metabolism of membrane phospholipids is disturbed in215
neurodegenerative disorders, producing changes in membrane216
properties such as permeability, ﬂuidity and alterations in ion217
homeostasis. This process is caused by overactivation of phos-218
pholipases, leading to phospholipid degradation and resulting in219
the generation of second messengers, which are associated with220
neurodegeneration [30]. In Alzheimer’s disease, abnormalities in221
membrane phospholipids are principally related to overactivation222
of phospholipase A2, or PLA2 [31], which catalyzes the hydrolysis of223
the ester bonds liberating fatty acids (FA) and lyso-phospholipids.224
This enzymatic stimulation leads to decreased total levels of phos-225
pholipids and accumulation of their degradation products [9,32].226
Moreover, the release and oxidation of arachidonic acid, one of227
the most abundant fatty acids contained in neural phospholipids,228
produces several lipid mediators closely associated with neuronal229
pathways involved inAD, such as eicosanoids or peroxidationprod-230
ucts as 4-hydroxy-2-nonenal [33]. On the other hand, there are also231
evidences for a role of phospholipases C and D in AD, although232
they have been much less studied. PLC hydrolyzes the phospho-233
diester bond at the sn-3 position forming 1,2-diacylglycerol (DAG)234
and a free base, while PLD cleaves phospholipids into phospha-235
tidic acid (PA) that can be latter converted to diacylglycerol by236
PA phosphatases. Therefore, both enzymatic reactions yield DAGs237
as ﬁnal product, which have unique functions as a basic compo-238
nent of membranes, intermediates in lipid metabolism and key239
element in lipid-mediated signaling [34]. In this context, previous240
reports have described increased levels of several isoenzymes of241
phosphoinositide-speciﬁc PLC [35,36] as well as PLD [37] in AD242
brains, and it has been demonstrated the involvement of PLD in243
APP trafﬁcking and A generation [38]. As a consequence, this244
abnormal metabolism results in important biochemical changes in245
brain, which is reﬂected in peripheral blood serum, as shown in246
Tables 1 and 2. A considerably decrease in diverse phosphocholine247
andethanolamine-plasmalogen specieswasobserved (Table2), but248
only in PUFA-containing phospholipids, indicating that membrane249
destabilization processes could be also related to imbalance in the250
levels of saturated/unsaturated fatty acids contained in the struc-251
ture of phospholipids, as recently reported [39]. In addition, the252
release of arachidonic acid from the hydrolysis of these phospho-253
lipids by PLA2 and subsequent action of cyclooxygenases (COXs)254
supports the elevation of serum prostaglandin levels (Table 1),255
which are important markers of oxidative stress. Finally, the pos-256
sible overactivation of phospholipases C and D in AD was also257
demonstrated, since it was found an increase in diacylglycerols258
(Table 1), not described to date in serum from AD patients. Thus,259
membrane breakdown highlights as a key factor in pathogenesis of260
AD, affecting numerous metabolites as summarized in Fig. 3.261
Fig. 3. Membrane phospholipids degradation by phospholipases, showing com-
pounds up- (↑) and down-regulated (↓).
4.2. Oxidative stress 262
Oxidative stress is other important process implicated in neu- 263
rodegenerative diseases because the high-metabolic rate of brain 264
[2], resulting in decreased levels of antioxidant compounds and 265
increased markers of protein, lipid, and nucleic acid oxidation. 266
In this sense, alterations observed in imidazole and histidine 267
(decreased, Table 3) and prostaglandins levels (increased, Table 1) 268
could be related with this oxidative damage. It has been previ- 269
ously reported a decrease in imidazole containing aminoacids in 270
plasma, urine and cerebrospinal ﬂuid (CSF) of AD patients [40]. His- 271
tidine, carnosine and anserine are antioxidant compounds involved 272
in the protection against oxidative damage due to the presence of 273
the imidazole ring in their structures, which can provide chelat- 274
ing properties for divalent ions, prevention of lipid peroxidation 275
and acting as quencher of 4-hydroxy-2-nonenal and malonalde- 276
hyde. However, no data about decreased levels of free imidazole in 277
AD (Table 3) has been previously reported. On the other hand, the 278
appearance of several markers of oxidative stress in AD samples, 279
such as prostaglandins (Table 1), is a typical ﬁnding in neurode- 280
generative disease research [11], as it has been described in the 281
previous section. 282
4.3. Hyperammonaemia 283
Signiﬁcant low levels of guanidine and arginine were observed 284
inAD(Table3), notdescribedpreviously toourknowledge, suggest- 285
ing an alteration in the guanidine cycle. This cycle, in conjunction 286
with urea cycle, is the responsible for nitrogen reutilization [41], 287
and control of the ammonia concentrations in the organism. In 288
brain, ammonia concentrations are maintained at low values in 289
healthy persons due to the action of a series of enzymes, princi- 290
pally glutamine synthetase. However, disorders in urea-guanidine 291
cycle may cause high amounts of ammonia, or hyperammonaemia, 292
which have deleterious effects on the central nervous system [42]. 293
In Alzheimer’s disease the alteration of urea cycle has been recently 294
discussed, and it has been found that enzymes of this cycle and the 295
corresponding genes have altered levels of expression [43]. Thus, 296
the involvement of hyperammonaemia in AD appears clear, and 297
alterations in this regulatory cycle were demonstrated considering 298
the low levels of guanidine and arginine shown in Table 3. 299
4.4. Other alterations in central nervous system 300
Other metabolites involved in different processes related to the 301
integrity of the central nervous system (CNS) were altered in AD 302
samples, such as putrescine, taurine and oleamide (decreased), 303
and kynurenine (increased). Putrescine is a polyamine with several 304
functionswithin theCNS, includingnervegrowthand regeneration, 305
modulation of N-methyl-d-aspartate (NMDA) receptor or protec- 306
tion over stress. Amyloid beta deposition is responsible for the 307
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up-regulation of polyaminemetabolism,with increased polyamine308
uptake and elevated ornithine decarboxylase (ODC) activity [44].309
Thus, it was found that changes in polyamine system causes a310
decrease in putrescine levels in brain of AD patients [45], which is311
in agreementwith results in blood serum shown in Table 3. Taurine312
is an amino acid present at high concentrations in the mammalian313
brain with several roles in neurotransmission, neuromodulation,314
osmoregulation, control of calcium inﬂux, and cell excitability. It315
has been demonstrated its potential role in preventing the neu-316
rotoxicity of beta amyloid and glutamate receptor agonists [46],317
and in this sense, it have already been reported lower levels in CSF318
of AD patients [47]. On the other hand, oleamide is an amidated319
lipid normally found in the brain and blood of mammals, including320
humans [48], where interacts with several neurotransmission sys-321
tems, enhancing the action of serotonin and GABA receptors [49].322
Modulation of memory by this lipid has been reported in rats [50],323
and it has been demonstrated its improving effects over choline324
acetyltransferase in vitro, whose reduced activity is closely related325
to AD [51]. However, there are not studies about physiological lev-326
els of oleamide in AD, but the decrease observed in Table 1 for this327
compound could be related to analogous decrease in neurotrans-328
mitters serotonin and GABA, previously found by other authors329
[52,53]. Finally, it is known the implication of up-regulated kynure-330
nine pathway (KP) in Alzheimer’s disease, by overexpression of331
indole 2,4 dioxygenase [54]. In this way, high conversion of trypto-332
phan (TRP) into kynurenine (KYN) is found, which ﬁnally leads to333
altered synthesis of relatedneuroactive compoundsas kynurenic or334
quinolinic acids. Thus, experimental increase observed for kynure-335
nine in AD (Table 3) may be related to other previous results, such336
as increased KYN/TRP quotient and quinolinic acid levels, accom-337
panied by a decrease of kynurenic acid levels [55].338
5. Conclusions339
The important role of lipids in Alzheimer’s disease pathogen-340
esis has been previously reported, and was conﬁrmed by results341
obtained in the present study. It has been demonstrated that342
comprehensive metabolic ﬁngerprints can be obtained by direct343
infusion mass spectrometry of serum samples extracted with a344
mixture of chloroform and methanol. This methodology allows345
simple, fast and reliable comprehensive metabolomic ﬁngerprint-346
ing of serum, a sample of high clinical value. In addition the347
application of thismethod to samples fromADpatients andhealthy348
controls allowed their discrimination. We observed alterations349
in the levels of diacylglycerols, prostaglandins and phospholipids350
that can be related to metabolic disorders associated to AD,351
such as oxidative stress and membrane breakdown. It was also352
observed a decrease of oleamide, involved in the suitable oper-353
ation of central nervous system. Moreover, other metabolites of354
lower molecular weight involved in hyperarmmonaemia (guani-355
dine, arginine), oxidative stress (histidine, imidazole) or polyamine356
system (putrescine) also exhibited changes of expression inAD, and357
may be candidates to be used as biomarkers of the disease.358
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